These cumulative observations position MYB as a master regulatory node in AML biology, perpetuating LSC functionality through integrated control of oncogenic cascades while emerging as a stratification marker for treatment-refractory disease and therapeutic targeting opportunities. This evidence concerns the gene MYB and acute myeloid leukemia.